Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
QR-421a
DRUG
2 trials
Sponsors
ProQR Therapeutics
, Laboratoires Thea
Conditions
Deaf Blind
Eye Diseases
Eye Diseases, Hereditary
Eye Disorders Congenital
Retinal Disease
Retinitis Pigmentosa
Usher Syndrome Type 2
Vision Disorders
Phase 1
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
Completed
NCT03780257
ProQR Therapeutics
Deaf Blind, Eye Diseases, Eye Diseases, Hereditary +5
Start: 2019-03-06
End: 2021-10-14
Updated: 2022-04-20
Phase 2
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
Terminated
NCT05176717
Laboratoires Thea
Deaf Blind, Eye Diseases, Eye Diseases, Hereditary +5
Start: 2021-12-15
End: 2022-08-02
Updated: 2024-08-07
Related Papers
QR‐421a RNA therapy in retinitis pigmentosa due to mutations in USH2A: Stellar trial Phase[AP1] 1b/2 interim results
Acta Ophthalmologica
2022-01-01
11 citations
Retinal Gene Therapy for Usher Syndrome: Current Developments, Challenges, and Perspectives
International Ophthalmology Clinics
2021-09-28
14 citations